Home

SURENDRA K AJJARAPU

CIK 1368298 · Chairman and CEO · last filed 2026-06-25

SURENDRA K AJJARAPU is a Chairman and CEO who has filed 21 SEC Form 4 insider transactions across 5 companies since 2020. The most recent filing shows the insider was granted $1.0M of WGRX on Jun 25, 2026. Across all open-market trades the lifetime net is +$130.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $28.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$28.49M

Companies

5

Total Filings

21

Lifetime Open-Market Net

$130.01M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
WGRX Director 7,971,511 $3.52 $28.06M $0 4 2026-06-25
MEDS Chairman and CEO 120,844 $3.55 $429.0K $130.01M 7 2024-05-28
Tevogen Bio Holdings Inc. (LGSTW) Delisted CEO and Chairman 8,988,889 $0.06 $540.2K $0 2 2023-06-21
Ocean Biomedical, Inc. (OCEAW) Delisted Director 258,200 $0.03 $7.7K $0 2 2023-03-24
Ocean Biomedical, Inc. (AEHAW) Delisted Chief Executive Officer — $0.16 — $0 1 2021-12-16

Recent Filings

21 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-25 WGRX Grant (A) +5,000,000 $1.00M EDGAR
2026-06-25 WGRX Exer (X) +100,000 $500 EDGAR
2026-04-23 WGRX Grant (A) +5,000,000 $1.00M EDGAR
2025-03-25 WGRX Grant (A) +4,082,247 $0 EDGAR
2024-05-28 MEDS Grant (A) +10,000 $0 EDGAR
2024-01-16 MEDS Grant (A) +150,000 $0 EDGAR
2023-06-21 Tevogen Bio Holdings Inc. (LGSTW) Delisted Grant (A) +7,988,889 $0 EDGAR
2023-06-12 Tevogen Bio Holdings Inc. (LGSTW) Delisted Grant (A) +1,000,000 $0 EDGAR
2023-03-24 Ocean Biomedical, Inc. (OCEAW) Delisted Other (J) −1,050,000 $0 EDGAR
2023-03-02 Ocean Biomedical, Inc. (OCEAW) Delisted Mixed −3,795,000 $0 EDGAR
Showing 1–10 of 21
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.